Mattson Financial Services LLC Has $1.71 Million Stock Holdings in Pfizer Inc. $PFE

Mattson Financial Services LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 30.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,338 shares of the biopharmaceutical company’s stock after selling 31,055 shares during the quarter. Mattson Financial Services LLC’s holdings in Pfizer were worth $1,705,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. lifted its stake in shares of Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after buying an additional 17,957,928 shares during the last quarter. Amundi lifted its stake in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Pfizer in the first quarter worth $389,861,000. Goldman Sachs Group Inc. lifted its stake in shares of Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after buying an additional 4,629,976 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Price Performance

NYSE:PFE opened at $24.22 on Friday. The stock has a market cap of $137.70 billion, a P/E ratio of 12.88, a PEG ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.53. The company has a fifty day moving average price of $24.89 and a 200 day moving average price of $24.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.